A5063300526- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- COVID-19 and healthcare impacts
- Occupational and environmental lung diseases
- CAR-T cell therapy research
- Peptidase Inhibition and Analysis
- HER2/EGFR in Cancer Research
- Economic and Financial Impacts of Cancer
- Neuroendocrine Tumor Research Advances
- Pleural and Pulmonary Diseases
- Radiomics and Machine Learning in Medical Imaging
- Monoclonal and Polyclonal Antibodies Research
- Immunotherapy and Immune Responses
- Ferroptosis and cancer prognosis
- Gastric Cancer Management and Outcomes
- Multiple and Secondary Primary Cancers
- Immune cells in cancer
- Advances in Oncology and Radiotherapy
- Cancer therapeutics and mechanisms
- Pancreatic and Hepatic Oncology Research
- Chronic Lymphocytic Leukemia Research
University Hospital of Lausanne
2016-2025
University of Lausanne
2016-2025
European Society for Medical Oncology
2017-2024
Hôpital Orthopédique de la Suisse Romande
2009-2024
Swiss Cancer Center Léman
2021-2023
Leman University
2023
Centre universitaire de médecine générale et santé publique, Lausanne
2022
European Thoracic Oncology Platform
2022
Heidelberg University
2021
University Hospital Heidelberg
2021
In an early-phase study involving patients with advanced non–small-cell lung cancer (NSCLC), the response rate was better nivolumab plus ipilimumab than monotherapy, particularly among tumors that expressed programmed death ligand 1 (PD-L1). Data are needed to assess long-term benefit of in NSCLC.
Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system (CNS) efficacy in the treatment ALK-positive non-small-cell lung cancer (NSCLC). We investigated alectinib as compared with crizotinib patients previously untreated, advanced NSCLC, including those asymptomatic CNS disease.In randomized, open-label, phase 3 trial, we randomly assigned 303 NSCLC to receive either (600 mg twice daily) or (250 daily). The primary end point...
Primary lung cancer remains the most common malignancy after non-melanocytic skin cancer, and deaths from exceed those any other worldwide [1.IARC. Cancer Incidence, Mortality Prevalence Worldwide GLOBOCAN 2012. http://gco.iarc.fr/Google Scholar]. In 2012, was frequently diagnosed in males with an estimated 1.2 million incident cases worldwide. Among females, leading cause of death more developed countries second less The highest incidence is found Central/Eastern Europe Asia...
HER2 mutations are identified in approximately 2%of non-small-cell lung cancers (NSCLC). There few data available that describe the clinical course of patients with HER2-mutated NSCLC. We retrospectively 65 NSCLC, diagnosed a in-frame insertion exon 20. collected clinicopathologic characteristics, patients' outcomes, and treatments. mutation was (1.7%) 3,800 tested almost an exclusive driver, except for one single case concomitant KRAS mutation. Our population presented median age 60 years...
Pembrolizumab monotherapy has shown antitumor activity in patients with small-cell lung cancer (SCLC). The randomized, double-blind, phase III KEYNOTE-604 study compared pembrolizumab plus etoposide and platinum (EP) placebo EP for previously untreated extensive-stage (ES) SCLC.Eligible were randomly assigned 1:1 to 200 mg once every 3 weeks or saline up 35 cycles 4 of EP. Primary end points progression-free survival (PFS; RECIST version 1.1, blinded central review) overall (OS) the...
These EANO–ESMO joint recommendations for the diagnosis and treatment of leptomeningeal metastasis (LM) from solid cancers represent first European guideline initiative on this topic. LM is defined as spread tumour cells within leptomeninges subarachnoid space, synonymous with ‘neoplastic meningitis’ can be further denoted by primary carcinomatosis, gliomatosis or lymphomatosis. The address tumours, but neither brain tumours nor lymphoma leukaemia.
Checkpoint inhibitors targeting programmed cell death 1 or its ligand (PD-L1) as monotherapies in combination with anti-cytotoxic T-lymphocyte-associated antigen 4 have shown clinical activity patients metastatic non-small lung cancer.To compare durvalumab, without tremelimumab, chemotherapy a first-line treatment for cancer.This open-label, phase 3 randomized trial (MYSTIC) was conducted at 203 cancer centers 17 countries. Patients treatment-naive, who had no sensitizing EGFR ALK genetic...
The ALEX study demonstrated significantly improved progression-free survival (PFS) with alectinib versus crizotinib in treatment-naive ALK-positive non-small-cell lung cancer (NSCLC) at the primary data cut-off (9 February 2017). We report mature PFS (cut-off: 30 November 2018) and overall (OS) up to 5 years 29 2019).Patients stage III/IV NSCLC were randomized receive twice-daily 600 mg (n = 152) or 250 151) until disease progression, toxicity, withdrawal death. Primary end point:...